Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Study of TLN-232 as Second-line Therapy for Patients With Metastatic Melanoma

NCT00735332 is registered in ClinicalTrials.gov with Thallion Pharmaceuticals as lead sponsor.

NCT NCT00735332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00735332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Study of TLN-232 as Second-line Therapy for Patients With Metastatic Melanoma
Lead sponsor
Thallion Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2008
Completion date
October 31, 2010
Enrollment
49 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma